Abstract 288P
Background
The family planning program curated by the Indonesian government to limit population growth has been successful. Hormonal contraception contains progesterone and estrogen, risk factors for breast cancer. Breast cancer is a prominent health issue in Indonesia as it has a high incidence rate and accounts for the second-highest mortality in women. the purpose of this research, looking at how the effect of hormonal contraceptives on estradiol and progesterone levels in breast cancer patients.
Methods
a six-year prospective cohort study at Dr. Moewardi Hospital. There are two groups of subjects with and without hormonal contraceptives. Data on breast cancer stage, tumor characteristics, estradiol levels, and progesterone levels were collected. The data are presented in mean, standard deviation, and distribution frequency (%). Statistical tests using Chi-square, Fisher exact, Mann-Whitney, and an independent t-test.
Results
303 samples were aged 31 to 78 years. 51% grade III, 28.7% Luminal B, and 45.9% LABC. 54.1% high estradiol levels, and 80.5% normal progesterone levels. The use of contraceptives, the type, duration of use, and duration of discontinuation of contraceptives do not affect estradiol and progesterone levels (p>0.05). Estradiol levels affect PFS, DFS, and OS (p<0.05) while progesterone levels have no effect (p>0.05). The type and duration of contraceptive use do not affect PFS, DFS, and OS (p>0.05). While the duration of discontinuation of contraceptives affects the OS (p<0.05) but not PFS and DFS (p>0.05).
Conclusions
PFS, DFS, and OS in breast cancer are affected by significantly high levels of estradiol, and in contrast, progesterone levels tend to be normal and not significantly affected. Lower levels of estradiol are associated with a better OS. A shorter duration for stopping the use of contraceptives is associated with a worse OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
303P - Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung cancer surgery
Presenter: Ji Hyung Hong
Session: Poster viewing 04
306P - Multimodal management and outcomes of stage III non-small cell lung cancer: KINDLE-Egypt analysis
Presenter: Rasha Aboelhassan
Session: Poster viewing 04
307P - Differential expression profiling of transcripts in stage IIIA non-small cell lung cancer (NSCLC) of smokers and non-smokers cases of north India: A geneto-environmental study
Presenter: Archana Mishra
Session: Poster viewing 04
308P - Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Presenter: Masanao Nakashima
Session: Poster viewing 04
309P - Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
Presenter: Saori Murata
Session: Poster viewing 04
311P - Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer in Thailand
Presenter: Sermsiri Sangroongruangsri
Session: Poster viewing 04
312P - ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling
Presenter: Allen Chi Shing Yu
Session: Poster viewing 04
313P - A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Presenter: Yongfeng Yu
Session: Poster viewing 04